摘要
目的:评价卡巴拉汀治疗阿尔茨海默病(Alzheimerdisease,AD)的临床效果和安全性。方法:实验于2004-11在暨南大学附属第一医院进行,应用Meta分析方法对5项研究卡巴拉汀治疗AD的自身前后对照实验进行再分析,评价其综合的显著性差异和效应大小。结果:①卡巴拉汀治疗前后的简明精神状态评分比较:综合检验Z=5.62,自由度10,P<0.001;ES:d=0.53。②卡巴拉汀治疗前后的Blessed-Roth评分比较:综合检验Z=4.53,自由度10,P<0.002;ES:d=0.44。③卡巴拉汀治疗前后的AD痴呆量表评分比较:综合检验Z=2.56,自由度6,P<0.05;ES:d=0.27。④5项研究中报道的药物不良反应的发生率为12.9%～28.8%,主要为胃肠道反应。结论:卡巴拉汀是一种治疗AD安全、有效的药物。
AIM: To assess the effectiveness and reliability of rivastigmine for treatment of Alzheimer disease (AD).METHODS: The experiment was finished in the First Affiliated Hospital of Jinan University in November 2004.Five self- controlled trials of rivastigmine in the treatment of AD were analyzed with Meta- analysis, and synthetically significant difference and effect size were evaluated.RESULTS:① The scores of MMSE before treated with rivastigmine were compared with those after the treatment, compositive test:Z=5.62, degree of freedom:10,P < 0.001; effect size:d=0.53. ② The comparison in scores of Blessed- Roth before and after treatment with rivastigmine,compositive test:Z=4.53, P < 0.002;effect size: d=0.44. ③ The comparison in scores of ADAS before and after treatment with rivastigmine,compositive test:Z=2.56,P < 0.05; effect size:d=0.27. ④ In 5 studies, the incidence of side reaction was between 12.9% and 28.8% , which mainly was a gastrointestinal symptom.
出处
《中国临床康复》
CAS
CSCD
北大核心
2005年第9期10-11,共2页
Chinese Journal of Clinical Rehabilitation
